- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01374711
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
June 26, 2013 updated by: Peter Pickkers, Radboud University Medical Center
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia. A Parallel Randomized Double-blind Placebo-controlled Study
The human body knows a biphasic immunological reaction to sepsis.
First, the pro-inflammatory reaction takes place, marked by the release of pro-inflammatory cytokines like TNF-α, as a reaction to the bacterial toxins.
Secondly, the counter regulatory anti-inflammatory reaction arises.
This phase is acting as negative feedback on the inflammation by inhibition of the pro-inflammatory cytokines.
This is called "immunoparalysis", a pronounced immunosuppressive state, which renders patients vulnerable to opportunistic infections.
Most of the septic patients survive the initial pro-inflammatory phase, but die during this second stage.Research in the past has shown that immunostimulatory therapy with GM-CSF or IFN-γ has promising effects on the pro-inflammatory reaction during immunoparalysis ex vivo.
Both drugs are known for their immunostimulatory effects.
Recent pilot studies have showed in septic patients, that long-lasting monocyte deactivation in sepsis ex vivo can be reversed by these two immunostimulants.
However, the mechanism and extent of immunoparalysis recovery may be different between the two compounds.
Previously it has been shown that human endotoxemia (induced by LPS), leads to marked immunosuppression in healthy individuals, characterized by a transient refractory state to a subsequent LPS challenge (endotoxin tolerance).
Consequently, human endotoxemia can serve as a standardized, controlled model for sepsis-induced immunoparalysis.
Until now, all studies have focused on the ex vivo tolerance.
However, we have recently proved, that the ex vivo condition is not completely representative for the in vivo situation.
Ex vivo, leukocyte tolerance to LPS resolves within one day, while the in vivo immunoparalysis persists for two weeks.
In this project, we will investigate the effects of both GM-CSF and IFN-γ in a parallel double-blind placebo controlled randomized manner on the immunoparalysis following human endotoxemia, both in-vitro and in vivo.
As a result, we hope to get more insight in the pathophysiology of sepsis-induced immunoparalysis and thereby develop new immunostimulatory therapies that improve patient outcome
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Radboud University Nijmegen Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male volunteers
Exclusion Criteria:
- seropositivity for markers of hepatitis B or HIV infection or medical history of any other obvious disease associated with immune deficiency
- Use of any medication or drugs
- a history of adverse reaction or hypersensitivity to GM-CSF/ IFN-γ
- Smoking.
- Previous spontaneous vagal collapse.
- History, signs or symptoms of cardiovascular disease.
- (Family) history of myocardial infarction or stroke under the age of 65 years.
- Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.
- Hypertension (defined as RR systolic > 160 or RR diastolic > 90) or hypotension (defined as RR systolic < 100 or RR diastolic < 50).
- Renal impairment (defined as plasma creatinin >120 μmol/l).
- Liver enzyme abnormalities or positive hepatitis serology.
- Febrile illness during the week before the LPS challenge
- Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.
- Chronic hiccups (defined as hiccups longer than 15 minutes in the past 6 months)
- Pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including diabetes and auto-immune diseases.
- Pre-existent lung disease
- Upper airway / esophageal pathology
- Recent (< 1 month) nasal bleeding
- Phrenic nerve lesions
- Any metals in body (pacemaker, splinters, metal stitches)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: placebo
LPS will be administered twice on days 1 and 7.
In between placebo will be administered on days 2, 4 and 6 subcutaneously.
|
2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
|
ACTIVE_COMPARATOR: GM-CSF
LPS will be administered twice on days 1 and 7.
In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
|
2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
|
ACTIVE_COMPARATOR: IFN-y
LPS will be administered twice on days 1 and 7.
In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
|
2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the effects of GM-CSF/IFN-γ on the development of in vivo immunoparalysis induced by experimental human endotoxemia
Time Frame: 1 week (day 1- day 8)
|
This will be determined by measuring plasma levels of various pro and anti-inflammatory cytokines and assessing the difference in the LPS-induced cytokine response between day 1 and 7
|
1 week (day 1- day 8)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The effects of GM-CSF/IFN-γ on the ex-vivo responsiveness of leukocytes to various inflammatory stimuli
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
the effects of GM-CSF/IFN-γ on monocyte HLA-DR expression
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
the effects of GM-CSF/IFN-γ on transcriptional pathways of leukocytes (qPCR and microarray)
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
the effects of GM-CSF/IFN-γ on urine markers of tubular injury
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
The effect of LPS on twitch transdiaphragmatic pressure
Time Frame: 1 day
|
1 day
|
the effects of GM-CSF/IFN-γ on clinical symptoms (illness score, mean arterial pressure, heart rate and temperature)
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
the effects of GM-CSF/IFN-γ on changes in phenotype and gene expression caused by mechanisms other than changes in the underlying DNA sequence
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
Beta 2 Glycoprotein and platelet-monocyte interactions post-LPS
Time Frame: 1 day
|
1 day
|
Macrophage differentiation
Time Frame: 1 day
|
1 day
|
Immunosuppressive neutrophil populations
Time Frame: 1 week (day 1- day 8)
|
1 week (day 1- day 8)
|
Blood viscosity
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Peter Pickkers, Prof, MD, PhD, Radboud University Nijmegen Medical Centre, The Netherlands
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (ACTUAL)
November 1, 2011
Study Completion (ACTUAL)
November 1, 2011
Study Registration Dates
First Submitted
May 19, 2011
First Submitted That Met QC Criteria
June 15, 2011
First Posted (ESTIMATE)
June 16, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
June 27, 2013
Last Update Submitted That Met QC Criteria
June 26, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL36068.091.11 BI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on E.coli endotoxin
-
University of AarhusCompletedSystemic Inflammatory Response SyndromeDenmark
-
National Institute of Environmental Health Sciences...National Center for Research Resources (NCRR)Completed
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompleted
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, SeasonalUnited States
-
University of Alabama at BirminghamAmerican Fibromyalgia Syndrome AssociationCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingDepression | Inflammation | Anhedonia | Anxiety | AgingUnited States
-
Michael Irwin, MDRecruitingDepression in Old AgeUnited States
-
Jian-cang Zhou M.D.CompletedCommunity Acquired InfectionChina